AMRI Acquires Pilot Plant Facilities in India; Manufacture of Custom Pilot Scale Intermediates by Second Quarter 2008.

ALBANY, N.Y. -- AMRI (NASDAQ: AMRI) has completed a company purchase of FineKem Laboratories Pvt. Limited, a manufacturing facility located in Aurangabad, India. This acquisition will significantly accelerate AMRI's ability to make custom pilot scale intermediates in India, which is expected to commence in the second quarter of 2008.

Expanding on the company's acquisition of manufacturing facilities in Aurangabad and Navi Mumbai in July 2007, the addition of custom pilot scale manufacturing also complements AMRI's current chemical development process capabilities in Hyderabad, India. Additionally, the purchase ensures the addition of another compound, ISMN (Isosorbide Mononitrate), to AMRI's generics portfolio.

AMRI intends to implement upgrades over the next few months to bring the existing facilities into compliance with U.S. Food and Drug Administration regulations for manufacturing clinical trial materials and commercial drug substances. Anticipated costs related to purchase and upgrades are not expected to be material to AMRI's results of operations or financial position.

In conjunction with the purchase, FineKem's managing director, Mr. Rakesh Doshi, will join AMRI India PVT Limited as executive director and COO reporting to Dr. Prasad Raje, managing director of AMRI's current Aurangabad and Navi Mumbai facilities.

"We are pleased to announce the addition of this new product offering," said AMRI Chairman, President and CEO Thomas E. D'Ambra, Ph.D. "As we continue to explore and expand the ability of AMRI to provide value and flexibility around the globe, the purchase of this site increases the cost-competitive solutions available to our customers for their outsourcing needs."

Founded in 1991, Albany Molecular Research, Inc. (AMRI) provides scientific services, products and technologies focused on improving the quality of life. AMRI works on drug discovery and development projects and conducts manufacturing of active ingredients and pharmaceutical intermediates for many of the world's leading healthcare companies. As an additional value added service to its customers, the company is also investing in R&D in order to expand its contract services and to identify novel early stage drug candidates with the goal to outlicense to a strategic partner. With locations in the U.S., Europe, and Asia, AMRI provides customers with a wide range of services, technologies and cost models.

Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. These statements may be identified by forward-looking words such as "may," "could," "should," "would," "will," "intend," "expect," "anticipate," "believe" and "continue" or similar words. Readers should not place undue reliance on our forward-looking statements. The company's actual results may differ materially from such forward-looking statements as a result of numerous factors, some of which the company may not be able to predict and may not be within the company's control. Factors that could cause such differences include, but are not limited to the company's ability to attract and retain experienced scientists, trends in pharmaceutical and biotechnology companies outsourcing of chemical research and development, the company's ability to enforce its intellectual property and technology rights, the risks posed by international operations to the company, and the company's ability to effectively manage its growth as well as those factors discussed in the company's Annual Report on Form 10-K for the year ended December 31, 2006 as filed with the Securities and Exchange Commission on March 15, 2007 and the company's other SEC filings. The company does not undertake any duty to and does not intend to update any forward-looking statements contained in this press release after the date of this press release.